|1.||Beer, Tomasz M: 46 articles (11/2015 - 01/2002)|
|2.||Georgoulias, V: 41 articles (07/2015 - 01/2000)|
|3.||Petrylak, Daniel P: 35 articles (12/2015 - 08/2002)|
|4.||Carducci, Michael A: 32 articles (04/2015 - 03/2002)|
|5.||Armstrong, Andrew J: 28 articles (10/2015 - 04/2005)|
|6.||Georgoulias, Vassilis: 28 articles (08/2015 - 04/2002)|
|7.||Fizazi, Karim: 27 articles (01/2016 - 09/2004)|
|8.||Figg, William D: 27 articles (01/2014 - 01/2003)|
|9.||Dreicer, Robert: 26 articles (08/2015 - 01/2003)|
|10.||Oudard, Stéphane: 26 articles (07/2015 - 05/2005)|
|1.||Breast Neoplasms (Breast Cancer)
07/01/2002 - "Docetaxel has proven efficacy in metastatic breast cancer. "
04/01/2000 - "Docetaxel has proven effective in advanced breast cancer. "
01/01/2005 - "High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer."
06/01/2002 - "The consistent demonstration of a high level of efficacy with manageable toxicity ensures the continued widespread investigation of docetaxel in metastatic breast cancer."
11/01/2008 - "At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role."
|2.||Prostatic Neoplasms (Prostate Cancer)
03/01/2014 - "Our findings, obtained with a highly clinically relevant prostate cancer model, suggest, for the first time, that docetaxel-based therapy of advanced human prostate cancer may be improved by combining docetaxel with Aneustat."
03/19/2013 - "Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1."
09/15/2010 - "Docetaxel is one of the few chemotherapeutic drugs that are considered highly effective when used to treat prostate cancer patients that have relapsed and/or metastatic disease, it is therefore reasonable to expect further improvements in treatment outcomes when it is combined with other therapeutic agents active in prostate cancer. "
11/01/2014 - "Although docetaxel is still considered a mainstay of treatment in metastatic castrate-resistant prostate cancer (mCRPC), in the last few years, new agents have been developed to improve survival in this setting and reach a possible optimal personalized treatment strategy. "
12/01/2009 - "The finding of improved overall survival has significant implications since no therapy to date, except for docetaxel-based regimens, has been shown to improve overall survival in metastatic prostate cancer. "
03/18/2015 - "By contrast, selectively inhibiting BCL-XL did not suppress granulopoiesis but was highly efficacious in combination with docetaxel when tested against a range of solid tumors. "
03/01/2001 - "Docetaxel delayed tumor growth and enhanced the efficacy of radiation: it dramatically reduced TCD50 (radiation dose yielding 50% tumor cure) from the control value of 38.6 Gy to 11.8 Gy, for an enhancement factor of 3.27. "
04/01/2013 - "We designed a risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with cancer in order to determine the optimal dose according to age, comorbidity and functional status. "
01/01/2014 - "Anti-tumor efficacy of the PS-PDLLA/DCT NPs in PC-3 cells was significantly more potent than that of the group treated with commercially available DCT, Taxotere (P<0.05). "
06/01/2013 - "The ability to deliver the potent anti-cancer agent docetaxel via the oral route may enable the development of promising new treatment regimens with reduced toxicity, increased efficacy, and increased patient convenience. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/01/1999 - "Results of a multicenter phase III trial of docetaxel versus best supportive care for the first-line treatment of non-small cell lung cancer are pending. "
01/01/2003 - "The cytotoxic agent docetaxel not only has proven activity in non-small cell lung cancer-when used alone or in combination-but is also a potent radiosensitizer, and improved treatments are needed in all stages of this disease. "
10/01/2007 - "According to this meta-analysis, docetaxel is superior to vinca alkaloid-based regimens in terms of OS and safety for first-line therapy of advanced non-small cell lung cancer."
12/01/2009 - "To study a commonly used Astragalus-based herbal formula previously found effective in non-small cell lung cancer (NSCLC) on the pharmacokinetics of docetaxel in patients with NSCLC. "
09/01/2004 - "Although the validity of the results of this study is limited due to the small sample size, docetaxel appears effective in selected elderly patients with advanced non-small-cell lung cancer."
|5.||Stomach Neoplasms (Stomach Cancer)
02/01/2014 - "As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone. "
02/01/2014 - "The combination of docetaxel and S-1 (DS) therapy is effective in patients with unresectable gastric cancer and is expected to be a regimen in neoadjuvant setting for advanced gastric cancer. "
01/01/2013 - "Therefore, Plu-CLA is a potential intraperitoneal-route carrier for hydrophobic docetaxel for the effective treatment of peritoneal metastatic gastric cancer."
01/01/2005 - "The combination of docetaxel and capectabine was found to be well tolerated and effective in patients with advanced gastric cancer. "
04/01/2012 - "Our study, for the first time, rationally demonstrated that LDM docetaxel treatment used alone or combined with EGCG is effective and safe in preclinical settings of gastric cancer. "
|1.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)